NorthSea Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$80M
- Investors
-
8
NorthSea Therapeutics General Information
Description
Developer of novel and innovative therapeutic drugs designed to treat inflammatory, metabolic and liver diseases. The company's therapeutics treat dyslipidemia, insulin resistance, hepatic inflammation and fibrosis, preventing liver damage and restoring metabolic health, enabling healthcare providers to treat their patients and improve their lives.
Contact Information
Website
www.northseatherapeutics.comCorporate Office
- Paasheuvelweg 25-C6
- 1105 BP Amsterdam
- Netherlands
Corporate Office
- Paasheuvelweg 25-C6
- 1105 BP Amsterdam
- Netherlands
NorthSea Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 17-Dec-2021 | $80M | Completed | Clinical Trials - Phase 3 | ||
| 3. Early Stage VC (Series B) | 08-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 01-Jan-2018 | $29.5M | Completed | Clinical Trials - Phase 2 | ||
| 1. Early Stage VC (Series A) | 12-Dec-2017 | $29.5M | $29.5M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NorthSea Therapeutics Comparisons
Industry
Financing
Details
NorthSea Therapeutics Competitors (29)
One of NorthSea Therapeutics’s 29 competitors is Verona Pharma, a Corporate Backed or Acquired company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Akero Therapeutics | Corporate Backed or Acquired | South San Francisco, CA | ||||
| OrphoMed | Venture Capital-Backed | San Francisco, CA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ |
NorthSea Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NorthSea Therapeutics Patents
NorthSea Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024206117-A1 | Benzoic acid derivatives for use in methods of treating intestinal failure-associated liver disease in children | Inactive | 24-Mar-2023 | ||
| AU-2021405273-A1 | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis | Pending | 22-Dec-2020 | ||
| CA-3201254-A1 | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis | Pending | 22-Dec-2020 | ||
| EP-4267124-A1 | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis | Pending | 22-Dec-2020 | ||
| US-20240325336-A1 | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis | Pending | 22-Dec-2020 | A61K31/202 |
NorthSea Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NorthSea Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hercules Capital (San Mateo) | Lender/Debt Provider | Minority | ||
| Ysios Capital | Venture Capital | Minority | ||
| Sofinnova Investments | Venture Capital | Minority | ||
| venBio | Venture Capital | Minority | ||
| BioGeneration Ventures | Venture Capital | Minority |
NorthSea Therapeutics FAQs
-
When was NorthSea Therapeutics founded?
NorthSea Therapeutics was founded in 2017.
-
Where is NorthSea Therapeutics headquartered?
NorthSea Therapeutics is headquartered in Amsterdam, Netherlands.
-
What is the size of NorthSea Therapeutics?
NorthSea Therapeutics has 23 total employees.
-
What industry is NorthSea Therapeutics in?
NorthSea Therapeutics’s primary industry is Drug Discovery.
-
Is NorthSea Therapeutics a private or public company?
NorthSea Therapeutics is a Private company.
-
What is the current valuation of NorthSea Therapeutics?
The current valuation of NorthSea Therapeutics is .
-
What is NorthSea Therapeutics’s current revenue?
The current revenue for NorthSea Therapeutics is .
-
How much funding has NorthSea Therapeutics raised over time?
NorthSea Therapeutics has raised $150M.
-
Who are NorthSea Therapeutics’s investors?
Hercules Capital (San Mateo), Ysios Capital, Sofinnova Investments, venBio, and BioGeneration Ventures are 5 of 8 investors who have invested in NorthSea Therapeutics.
-
Who are NorthSea Therapeutics’s competitors?
Verona Pharma, Akero Therapeutics, OrphoMed, Apeptico, and Phathom Pharmaceuticals are some of the 29 competitors of NorthSea Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
